The Institute for Clinical and Economic Review (ICER) – an organization that produces reports that analyze the cost effectiveness of drugs and other medical services – has highlighted the improved cost-effectiveness of high cholesterol treatments inclisiran and bempedoic acid in patients who have … Read More
Advocacy and Policy
The FH Foundation started 2021 off with an impactful Listening Session with the Food and Drug Administration (FDA) Center for Drug Evaluation and Research Division of Diabetes, Lipid Disorders, and Obesity (DDLO) on Homozygous Familial Hypercholesterolemia (HoFH) on January 4. Kate Robinson and … Read More
The FH Foundation is pleased to report that the first-ever FH Advocacy Group in Iraq was launched on May 22, 2020. Ms. Fatima Lahmood, a strong FH warrior living with Familial Hypercholesterolemia (FH) and a pharmacy student, has taken on the leadership role as patient representative, working with … Read More
On January 28, 2020, the FH Foundation and some of our amazing community members and leaders, who are FH Advocates for Awareness, will go to Capitol Hill to ask our elected representatives for their continued support in prioritizing familial hypercholesterolemia (FH) as a public health concern and … Read More
The FH Foundation is a true partnership of individuals and families impacted by FH, and the healthcare professionals who diagnose and treat FH. Together, we are raising awareness of FH, driving improved diagnosis, making sure individuals know their treatment options and opportunities for clinical … Read More
On May 7, 2019 FH Advocate, April Donelson, chose to spend her birthday on Capitol Hill, advocating to make familial hypercholesterolemia (FH) a public health priority with Florida and Texas Congressional leaders. April shared “Ryan’s story” to make sure everyone understands the importance … Read More
Affordable prescription drugs are necessary so individuals can benefit from advances in medicine to treat conditions such as familial hypercholesterolemia. Medical research and innovation make it possible to actually prevent or delay heart disease in people born with FH. All it takes is early diagnosis … Read More
Ask the Pharmacy – Are you getting the lowest cost for your PCSK9 inhibitor?
The manufacturers of both PCSK9 inhibitors, Praluent and Repatha, have lowered the list price for these cholesterol-lowering treatments by 60% to $5,850 per year. As we reported in February, the FH Foundation continues … Read More
The FH Foundation welcomes Sanofi and Regeneron’s announcement today to lower the list price of its LDL cholesterol lowering treatment, the PCSK9 inhibitor Praluent, to $5,850 annually. This brings the list price of Praluent in line with Amgen’s PCSK9 inhibitor, Repatha, which was lowered … Read More
The FH Foundation went to Capitol Hill on January 28-29 to raise awareness of Familial Hypercholesterolemia among our nation’s elected officials, and advocate for Federal funding for FH research.
Our 2019 class of 25 new volunteer FH Advocates for Awareness held 36 meetings with Congressional Offices … Read More